196 related articles for article (PubMed ID: 12349828)
1. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
Ben-Gary H; McKinney RL; Rosengart T; Lesser ML; Crystal RG
Mol Ther; 2002 Aug; 6(2):287-97. PubMed ID: 12349828
[TBL] [Abstract][Full Text] [Related]
2. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.
Harvey BG; Hackett NR; El-Sawy T; Rosengart TK; Hirschowitz EA; Lieberman MD; Lesser ML; Crystal RG
J Virol; 1999 Aug; 73(8):6729-42. PubMed ID: 10400771
[TBL] [Abstract][Full Text] [Related]
3. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.
Harvey BG; Maroni J; O'Donoghue KA; Chu KW; Muscat JC; Pippo AL; Wright CE; Hollmann C; Wisnivesky JP; Kessler PD; Rasmussen HS; Rosengart TK; Crystal RG
Hum Gene Ther; 2002 Jan; 13(1):15-63. PubMed ID: 11779412
[TBL] [Abstract][Full Text] [Related]
4. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.
Crystal RG; Harvey BG; Wisnivesky JP; O'Donoghue KA; Chu KW; Maroni J; Muscat JC; Pippo AL; Wright CE; Kaner RJ; Leopold PL; Kessler PD; Rasmussen HS; Rosengart TK; Hollmann C
Hum Gene Ther; 2002 Jan; 13(1):65-100. PubMed ID: 11779413
[TBL] [Abstract][Full Text] [Related]
5. Host responses and persistence of vector genome following intrabronchial administration of an E1(-)E3(-) adenovirus gene transfer vector to normal individuals.
Harvey BG; Hackett NR; Ely S; Crystal RG
Mol Ther; 2001 Feb; 3(2):206-15. PubMed ID: 11237677
[TBL] [Abstract][Full Text] [Related]
6. Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo.
Hackett NR; El Sawy T; Lee LY; Silva I; O'Leary J; Rosengart TK; Crystal RG
Mol Ther; 2000 Dec; 2(6):649-56. PubMed ID: 11124067
[TBL] [Abstract][Full Text] [Related]
7. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications.
Joseph PM; O'Sullivan BP; Lapey A; Dorkin H; Oren J; Balfour R; Perricone MA; Rosenberg M; Wadsworth SC; Smith AE; St George JA; Meeker DP
Hum Gene Ther; 2001 Jul; 12(11):1369-82. PubMed ID: 11485629
[TBL] [Abstract][Full Text] [Related]
8. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus.
Harvey BG; Leopold PL; Hackett NR; Grasso TM; Williams PM; Tucker AL; Kaner RJ; Ferris B; Gonda I; Sweeney TD; Ramalingam R; Kovesdi I; Shak S; Crystal RG
J Clin Invest; 1999 Nov; 104(9):1245-55. PubMed ID: 10545523
[TBL] [Abstract][Full Text] [Related]
9. Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121.
Patel SR; Lee LY; Mack CA; Polce DR; El-Sawy T; Hackett NR; Ilercil A; Jones EC; Hahn RT; Isom OW; Rosengart TK; Crystal RG
Hum Gene Ther; 1999 May; 10(8):1331-48. PubMed ID: 10365664
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.
Rosengart TK; Lee LY; Patel SR; Sanborn TA; Parikh M; Bergman GW; Hachamovitch R; Szulc M; Kligfield PD; Okin PM; Hahn RT; Devereux RB; Post MR; Hackett NR; Foster T; Grasso TM; Lesser ML; Isom OW; Crystal RG
Circulation; 1999 Aug; 100(5):468-74. PubMed ID: 10430759
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve.
Rajagopalan S; Shah M; Luciano A; Crystal R; Nabel EG
Circulation; 2001 Aug; 104(7):753-5. PubMed ID: 11502697
[TBL] [Abstract][Full Text] [Related]
12. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121.
Lee LY; Patel SR; Hackett NR; Mack CA; Polce DR; El-Sawy T; Hachamovitch R; Zanzonico P; Sanborn TA; Parikh M; Isom OW; Crystal RG; Rosengart TK
Ann Thorac Surg; 2000 Jan; 69(1):14-23; discussion 23-4. PubMed ID: 10654479
[TBL] [Abstract][Full Text] [Related]
13. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector.
Harvey BG; Worgall S; Ely S; Leopold PL; Crystal RG
Hum Gene Ther; 1999 Nov; 10(17):2823-37. PubMed ID: 10584928
[TBL] [Abstract][Full Text] [Related]
14. Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma.
Topf N; Worgall S; Hackett NR; Crystal RG
Gene Ther; 1998 Apr; 5(4):507-13. PubMed ID: 9614575
[TBL] [Abstract][Full Text] [Related]
15. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.
Rosengart TK; Lee LY; Patel SR; Kligfield PD; Okin PM; Hackett NR; Isom OW; Crystal RG
Ann Surg; 1999 Oct; 230(4):466-70; discussion 470-2. PubMed ID: 10522716
[TBL] [Abstract][Full Text] [Related]
16. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis.
Crystal RG; McElvaney NG; Rosenfeld MA; Chu CS; Mastrangeli A; Hay JG; Brody SL; Jaffe HA; Eissa NT; Danel C
Nat Genet; 1994 Sep; 8(1):42-51. PubMed ID: 7527271
[TBL] [Abstract][Full Text] [Related]
17. [Aerosol administration of a replication defective recombinant adenovirus expressing normal human cDNA-CFTR in the respiratory tractus in patients with cystic fibrosis].
Bellon G; Calmard L; Thouvenot D; Levrey H; Jagneaux V; Poitevin F; Malcus C; Accart N; Séné C; Layani MP; Aymard M; Bienvenu J; Courtney M; Döring G; Gilly B; Gilly R; Lamy D; Morel Y; Paulin C; Perraud F; Rodillon L; So S; Touraine F; Schatz C; Pavirani A
C R Seances Soc Biol Fil; 1996; 190(1):109-42. PubMed ID: 8881273
[TBL] [Abstract][Full Text] [Related]
18. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype.
Mastrangeli A; Harvey BG; Yao J; Wolff G; Kovesdi I; Crystal RG; Falck-Pedersen E
Hum Gene Ther; 1996 Jan; 7(1):79-87. PubMed ID: 8825871
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine.
Crystal RG; Hirschowitz E; Lieberman M; Daly J; Kazam E; Henschke C; Yankelevitz D; Kemeny N; Silverstein R; Ohwada A; Russi T; Mastrangeli A; Sanders A; Cooke J; Harvey BG
Hum Gene Ther; 1997 May; 8(8):985-1001. PubMed ID: 9195221
[No Abstract] [Full Text] [Related]
20. VEGF gene therapy for coronary artery disease and peripheral vascular disease.
Rasmussen HS; Rasmussen CS; Macko J
Cardiovasc Radiat Med; 2002; 3(2):114-7. PubMed ID: 12699842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
